Kadcyla Intravenous infusion 160mg, manufactured by Chugai Pharmaceutical, contains Trastuzumab emtansine (genetical recombination). With YJ code 4291426D2022 and standard 160mg bottle, it is an antibody-drug conjugate used for HER2-positive metastatic breast cancer.
Kadcyla Intravenous infusion 160mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).